Alzheimer's Disease Trial, Recruiting NCT06121544 Sponsor: Skane University Hospital Condition: Alzheimer's Disease
Back to Alzheimers Disease

Alzheimer's Disease Trial, Recruiting

NCT06121544
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 50 and 80 years old.
  • If you are between 50 and 60 years old, you must have at least one of the following: you carry a gene variant called APOE-ε4, you have a close family member (parent or sibling) who developed dementia or serious memory loss before age 75, or tests have already shown signs of Alzheimer's-related protein buildup in your brain.
  • You score at or above a certain level on a standard memory and thinking test (confirm with trial site for exact score based on your age).
  • You score 12 or above on a telephone-based thinking and memory check called the MoCA.
  • You speak and understand Swedish well enough to take part in the study and complete cognitive tests without needing an interpreter.
  • You will be placed in one of two groups: one for people who show early signs of Alzheimer's disease based on brain or fluid tests, and one for people who do not show those signs.

Who may not be able to join:

  • You have already been diagnosed with mild cognitive impairment or dementia.
  • You have had a significant brain injury or another known brain or nervous system condition that has caused lasting thinking or memory problems.
  • You have experienced major depression, bipolar disorder, or repeated episodes of psychosis within the past year.
  • You have had problems with alcohol or drug misuse or dependence within the past year.
  • You have a serious or unstable illness, such as advanced cancer, that would make it hard to take part in the study.
  • You are unwilling or unable to complete the required baseline assessments, which include thinking and memory tests, a blood draw, an MRI scan, and a PET scan.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 30 June 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Skane University Hospital
Registry
ClinicalTrials.gov
Start date
1 April 2022
Est. completion
31 December 2026

Where this trial is recruiting

🇸🇪 Sweden

Primary endpoints

Change in cognitive function; Change in cognitive function - digital assessment

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov